IXICO PLC
Company Profile
Business description
IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.
Contact
15 Long Lane
4th Floor, Griffin Court
LondonEC1A 9PN
GBRT: +44 2037637499
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2025
Employees
74
Stocks News & Analysis
stocks
What does big US court decision mean for Google’s parent company Alphabet?
stocks
Is this still an ASX share to own forever?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,140.50 | 11.00 | 0.12% |
| CAC 40 | 7,656.10 | 42.82 | -0.56% |
| DAX 40 | 23,625.66 | 144.67 | -0.61% |
| Dow JONES (US) | 45,316.53 | 304.76 | -0.67% |
| FTSE 100 | 9,204.98 | 11.89 | -0.13% |
| HKSE | 25,417.98 | 359.47 | 1.43% |
| NASDAQ | 21,621.71 | 85.98 | -0.40% |
| Nikkei 225 | 43,018.75 | 438.48 | 1.03% |
| NZX 50 Index | 13,223.53 | 90.33 | 0.69% |
| S&P 500 | 6,464.58 | 37.50 | -0.58% |
| S&P/ASX 200 | 8,871.20 | 8.60 | 0.10% |
| SSE Composite Index | 3,812.51 | 46.64 | 1.24% |